Cytokine Induced Killer Cells Combined With TACE In The Treatment Of Primary Hepatocellular Carcinoma

BackgroundPrimary hepatocellular carcinoma is one of the most common malignant tumor worldwide. China is one of the high-prevalence area. Primary hepatocellular carcinoma is the second cancer-related deaths tumor behind the pulmonary cancer.PHC is not sensitive to radiation treatment and chemotherapy. The main treatment is surgical operation.However, most patients have lost the chance of operation when see doctor. Transcatheter arterial chemoembolization is the main treatment to patients who have lost the chance of operation. TACE also has disadvantages, for example, it would result in incomplete necrosis of the tumor and the immune function could be damaged after the operation.Cytokine induced killer cells is killer cells induced by many kinds of cytokines. It is separated from peripheral blood monocyte cells and then induced by cytokines. Cytokine induced killer cells is a kind of CD3+CD56+double positive cytotoxic cells. After transfusion of CIK cells, it could result in effect of anti-cancer through direct and indirect ways. CIK cell therapy has been the fourth method in treatment of PHC after operation, radiotherapy and chemotherapy. CIK cell is first found by Stanford university. It not only have the anti-cancer function of T lymphocyte, but also with the non-MHC restriction inhibition advantage of NK cell. Its activity could reach to84.7%. CIK cells have the advantages of proliferation rapidly, powerful activity and they also have effect on multidrug resistance tumors. However, they have no effect on normal cells. We obtain little peripheral blood monocyte cells and culter them ex vivo under specific condition. Then transfuse the CIK cells to patients. The CIK cells would exert the effect of anti-tumor. Nowadays, biotherapy has become an important auxiliary method of tumor therapy.ObjectiveTo analyze the treatment effect of the cytokine induced killer cells combined with TACE on the patients with Primary hepatocellular carcinoma.MethodsThe cases The cases of UC were collected from2008to2011.64patients with moderate or terminal PHC were all treated with TACE, and31of them were given CIK cell therapy after the TACE. We obtain peripheral blood monocyte cells and add cytokines such as INF-γ、CD3McAb、IL-2、IL-1a. After14to16days culturing, we obtain the CIK cells. Then detect the T cell subsets of the CIK cells by flow cytometry when the bacteria, mycoplasma, fugus and endotoxin was negative. At last, transfuse the CIK cells into the patients. After the CIK cell therapy, evaluate the survival rate, quality of life, clinical effciency, medical imaging and the adverse reaction of the treatment group and control group.ResultsWe follow up33patients of control group and find24patients alive after half a year. The rate of that is26patients out of31patients. A year later, patients still alive is17in control and20in treatment group. There is no significant difference in treatment and control group(P>0.05). After induced by some kinds of cytokines, the CD3+、 CD3+CD8+、CD3+CD4+、CD3+CD56+T lymphocytes increase significantly after CIK cells transfusion. However, only CD3+、CD3+CD56+、CD3+CD8+is found difference between the treatment and control group(P<0.05). The quality of life improve significantly in the treatment group. The half a year and one year CR+PR is33.3%and15.2%in control group. In treatment group, the rate is38.7%and25.8%.3patients have moderate fever but their temperature become normal in24h after given symptomatic therapy.ConclusionThe immunity function and quality of life improve after sequential therapy of TACE and CIK cell treatment. However, the survival rates do not change very much.